A Pilot Study of Sequential Vaccinations With ALVAC-CEA and Vaccinia-CEA With the Addition of IL-2 [interleukin-2] and GM-CSF [granulocyte-macrophage colony-stimulating factors] in Patients With CEA Expressing Tumors

Trial Profile

A Pilot Study of Sequential Vaccinations With ALVAC-CEA and Vaccinia-CEA With the Addition of IL-2 [interleukin-2] and GM-CSF [granulocyte-macrophage colony-stimulating factors] in Patients With CEA Expressing Tumors

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs ALVAC CEA (Primary) ; Vaccinia CEA (Primary) ; Interleukin-2; Sargramostim
  • Indications Cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top